SciBase signs distribution agreement in Switzerland

SciBase has signed a distribution agreement for Switzerland with CDP SWISS AG.
The sales and marketing effort of SciBase’s melanoma detection product Nevisense
will initially be focused on the nearly 400 dermatologists that work in private
clinics in Switzerland.
Switzerland is the country in Europe with the highest prevalence of malignant
melanoma. Each year approximately 2,500 new cases of the disease are diagnosed,
which makes the market potentially very interesting for SciBase. Approximately
70 percent of the 500 dermatologists in Switzerland operate full time at private
clinics.

- Switzerland is one of Europe’s smaller markets, but we believe that there is
good potential there. A high proportion of skin cancer screenings take place in
private clinics – clinics that are usually more open to new methods. With CDP
SWISS AG we have a distributor with well-established contacts right into our
target customer and they have a good track record of similar products, says
Simon Grant, CEO of SciBase.

By signing an agreement with one of the premier distributors of medical devices
for dermatologists, SciBase will firmly establish Nevisense on the Swiss market.
While the focus of CDP SWISS AG will be private dermatologists, they will also
address the nine hospital-based public clinics as these clinics often evaluate
products and publish results – and this can in turn influence the private
clinics.

- We are very pleased to be able to represent SciBase and Nevisense in
Switzerland. With Nevisense, the health care system gains access to an objective
tool which helps to identify early stage malignant melanoma that in the end
might save lives. There is a great interest in methods to improve diagnosis and
many Swiss Doctors have heard of Nevisense from their German colleagues, says
Falk Dörstling, CEO of CDP SWISS AG.

CDP SWISS AG specialize on medical technology products for dermatologists, with
a focus on laser-based products. They offer a complete coverage of Switzerland.
The Company has been active for 10 years and has shown strong growth from the
start, thanks to their strong customer relationships.

For more information, please contact:

Simon Grant, CEO

Phone: +46 72 887 43 99

Email: simon.grant@scibase.com

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for
nearly half of all cancers. It has been estimated that nearly half of all
Americans who live to age 65 will develop skin cancer at least once. Malignant
melanoma is the most fatal form of skin cancer causing the majority (75%) of
deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new
cases of melanoma yearly.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.